Prediction of preeclampsia based on IGFBP-7

By measuring the amount of IGFBP-7 biomarker in pregnant subjects and comparing it, the problem of inaccurate diagnosis of preeclampsia in the prior art is solved, and early and reliable prediction of the risk of pregnancy hypertension disease is achieved, and the Proper management measures are carried out based on scientific evidence, which improves the accuracy and efficiency of diagnosis.

CN112673259BActive Publication Date: 2024-11-22F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980061661.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-07-20
Filing Date
2019-07-19
Publication Date
2024-11-22
Estimated Expiration
2039-07-19

AI Technical Summary

Technical Problem

Existing methods have inaccuracies in diagnosing and predicting pregnancy hypertensive diseases, especially preeclampsia, urine protein impregnation tablets are prone to errors and are not reliable enough, Doppler ultrasound examination requires professional technology, and it is impossible to identify risks early. , there is a lack of reliable biomarkers for early prediction.

Method used

In vitro detection using specific binding agents by measuring the amount of IGFBP-7 biomarker in pregnant subject samples and comparing with reference amounts to assess whether subjects are at risk for preeclampsia or preeclampsia-related conditions , assisted automation equipment for analysis.

Benefits of technology

It achieves rapid and reliable prediction of the risks of preeclampsia or preeclampsia-related diseases, can identify risk subjects early, provide scientific basis for appropriate management measures, and improves the accuracy and efficiency of diagnosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 44781
    Figure 44781
  • Figure 402412
    Figure 402412
  • Figure 412893
    Figure 412893
Patent Text Reader

Abstract

The present invention relates to a method for assessing whether a pregnant subject is at risk of developing pre-eclampsia or a pre-eclampsia-related condition, the method comprising the steps of determining the amount of the biomarker IGFBP-7 (insulin-like growth factor binding protein 7) in a sample from the subject, and comparing the determined amount of the biomarker with a reference. In addition, the present invention relates to the use in vitro of the biomarker IGFBP-7 or at least one detection reagent that specifically binds to IGFBP-7 in a sample from a pregnant subject for assessing whether the subject is at risk of developing pre-eclampsia or a pre-eclampsia-related condition. The present invention also includes a device adapted to implement the method of the present invention.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to a method for assessing whether a pregnant subject is at risk of developing pre-eclampsia or a condition associated with pre-eclampsia, the method comprising the steps of determining the amount of the biomarker IGFBP-7 (insulin-like growth factor binding protein 7) in a sample from the subject, and comparing the determined amount of the biomarker with a reference. In addition, the present invention relates to the in vitro use of the biomarker IGFBP-7 or at least one detection reagent that specifically binds to IGFBP-7 in a sample from a pregnant subject, for assessing whether the subject is at risk of developing pre-eclampsia or a condition associated with pre-eclampsia. The present invention also includes a device adapted to implement the method of the present invention.

[0002] Hypertensive disorders represent the most common medical complication of pregnancy, affecting approximately 6% to 8% of pregnancies (Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183(1):S1–S22). Pregnancy complications are associated with increased pregnancy-related mortality in pregnant women on the one hand, and with increased morbidity and mortality in the newborns on the other hand. Maternal mortality rates are even more frequent in pregnant women over the age of 39 years, with a rate of 14.5 per 100 000 live births.

[0003] Hypertensive disorders of pregnancy can be classified as 1) preeclampsia; 2) chronic hypertension (of any cause); 3) chronic hypertension superimposed on preeclampsia; and 4) gestational hypertension (ACOG Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013;122:1122-31). Clinical management usually includes: blood pressure control in the case of preeclampsia and chronic hypertension, seizure prevention in the case of severe hypertension or severe hypertension with eclamptic fit, earlier delivery (34 weeks vs 37 weeks) in the case of chronic hypertension superimposed on preeclampsia, and intensive postpartum monitoring in the case of gestational hypertension (NICE (2011) NICE clinical guideline 107: Hypertension in Pregnancy).

[0004] Preeclampsia is the most important hypertensive disorder during pregnancy and is associated with maternal and fetal / neonatal mortality and morbidity (Duley 2009, Semin Perinatol: 33: 130–37).

[0005] Pre-eclampsia is generally defined as pregnancy-related or induced hypertension. It is characterised by hypertension and proteinuria. Detailed information is also found in standard textbooks of medicine and in guidelines from various clinical societies (NICE (2011) NICE clinical guideline 107: Hypertension in Pregnancy).

[0006] Currently, there is no cure for preeclampsia other than delivery of the baby. The severity of preeclampsia can range from mild to life-threatening. Mild forms of preeclampsia can be treated with bed rest and frequent monitoring. For moderate to severe cases, hospitalization is recommended, and blood pressure medication or anticonvulsants to prevent seizures are prescribed. If the condition becomes life-threatening for the mother or baby, the pregnancy is terminated and the baby is delivered prematurely.

[0007] According to current guidelines, the diagnosis of pre-eclampsia is based on new-onset hypertension and proteinuria in pregnant women after the 20th week of gestation. In previously normotensive women, blood pressure greater than or equal to 140 mmHg systolic or greater than or equal to 90 mmHg diastolic on two occasions at least 4 hours apart after the 20th week of gestation is considered to be hypertension. Reliable detection of significant proteinuria is of utmost importance in women with new-onset hypertension during pregnancy, as it distinguishes pregnant women with pre-eclampsia from pregnant women with gestational hypertension and forms the basis for future monitoring and management. Significant proteinuria is internationally defined as urinary excretion of more than 300 mg of protein in a 24-hour period, and this is included in the definition of pre-eclampsia (NICE (2011) NICE clinical guideline 107: Hypertension in Pregnancy).

[0008] Proteinuria can be determined by 24-hour urine collection, protein / creatinine ratio calculation, or dipstick reading (Executive Summary: Hypertension in Pregnancy, American College of Obstetricians and Gynecologist, Obstet Gynecol 2013;122:1122-31).

[0009] The determination of proteinuria is usually done using a urine protein dipstick, as this method allows for rapid measurement of proteinuria. However, it is often fraught with incorrect results and is therefore a very inaccurate method of determining renal insufficiency. Furthermore, due to the variability of the qualitative determination, this method is not recommended for diagnostic use and should only be used when other quantitative methods cannot be used (ACOG Task Force, 2013). The higher incidence of incorrect urine dipstick results is particularly high in women with hypertension problems. Worryingly, up to 66% of hypertensive women with negative urine dipstick results are found to have significant proteinuria. "(North R. Classification and diagnosisof preeclampsia. In Preeclampsia: Etiology and Clinical Practice, pages 250-251).

[0010] A more accurate method of determining protein in urine is 24-hour urine measurement (usually greater than or equal to 300 mg of urine collected per 24-hour period to diagnose preeclampsia) or calculation of the protein-to-creatinine ratio (usually greater than or equal to 0.3, with each measurement measured in mg / dl). However, these methods also have certain disadvantages. For example, they are more time-consuming and, in some cases, are also prone to error. Bouzari et al. found that proteinuria (determined by 24-hour urine measurement) in patients with preeclampsia was associated with adverse pregnancy outcomes. However, it was not sufficient to be a predictor of adverse outcomes in preeclampsia (Bouzari Z, Javadiankutenai M, Darzi A, Barat S.: Clin Exp Obstet Gynecol. 2014;41(2):163-8). Zhang disclosed that this is not a reliable biomarker for predicting the onset of pre-eclampsia or HELLP syndrome in pregnant women (Zhang et al. Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet Gynecol 2001; 97:261-7). Similarly, Thangaratinam showed in a systematic review that proteinuria is a poor predictor of complications of pre-eclampsia (Thangaratinam et al. Estimation of proteinuria as a predictor of complications of pre-eclampsia: a systematic review. BMC Medicine 2009; 7:10).

[0011] Since pre-eclampsia is one of the main causes of perinatal morbidity and mortality, biomarkers are urgently needed to predict the disease. In particular, the prediction of early-onset pre-eclampsia is important in view of the serious side effects and adverse consequences associated therewith. In addition, the prediction of pre-eclampsia is decisive for the planning of preventive or therapeutic intervention studies (Ohkuchi 2011, Hypertension 58: 859-866). On the other hand, patients belonging to the risk group of increased risk of pre-eclampsia that can be excluded within a certain time window will require less intensive care and, in most cases, can be treated without rest (outpatient setting).

[0012] Doppler ultrasonography has been used to identify patients with abnormal uterine perfusion, and it has been suggested that those patients who demonstrate abnormal perfusion identified by Doppler ultrasonography are at risk for developing preeclampsia, eclampsia, and / or HELLP syndrome (Stepan 2007, Hypertension, 49:818-824; Stepan 2008, Am J Obstet Gynecol 198:175.e1-1). However, a disadvantage of Doppler ultrasonography is that it requires highly specialized medical practitioners to perform and evaluate the results.

[0013] Angiogenic factors and their antagonists have been proposed as indicators of pre-eclampsia. In particular, placental growth factor (PlGF) and soluble fsm-like tyrosine kinase 1 (sFlt-1) have been reported to be altered in patients with pre-eclampsia. Individual ratios of sFlt-1 and PlGF at different time points of pregnancy have been associated with the risk of pre-eclampsia (Kusanovic 2009, J of Maternal- Fetal and Neonatal Medicine 22(11): 1021-1038). WO 2013 / 068475 discloses a method for diagnosing whether a pregnant subject has a risk of developing pre-eclampsia within a short period of time based on a first and a second ratio of sFlt-1 and PlGF.

[0014] IGFBP-7 (insulin-like growth factor binding protein 7) is a 30 kDa modular glycoprotein known to be secreted by endothelial cells, vascular smooth muscle cells, fibroblasts and epithelial cells (Ono, Y., et al., Biochem BiophysRes Comm 202 (1994) 1490-1496). It has been described as a diagnostic or prognostic marker for various conditions. For example, it has been described as a biomarker for cancer, and anti-IGFBP-7 antibodies have been proposed as a diagnostic tool for detecting neoplastic diseases including tumor angiogenesis (WO 2010 / 043037). WO2008 / 089994 discloses the use of IGFBP-7 in the assessment of heart failure. The combination of urinary IGFBP-7 and TIMP-2 has been shown to be a sensitive and specific biomarker for predicting early acute kidney injury (AKI) after cardiac surgery and predicting renal recovery (Meersch et al. PLoS One. 2014Mar 27; 9(3)). EP2666872A1 discloses various markers for diagnosis and prognosis of renal injury and renal failure. One of the disclosed markers is IGFBP-7.

[0015] WO2017 / 148854 discloses a method for diagnosing pre-eclampsia or pre-eclampsia-related conditions (such as eclampsia, HELLP syndrome) in a pregnant subject. The document does not disclose the assessment of whether a pregnant subject is at risk of developing pre-eclampsia or a pre-eclampsia-related condition. Instead, the document focuses on identifying subjects who have already developed pre-eclampsia or a pre-eclampsia-related condition.

[0016] There is an urgent need to develop new biomarker-based methods to assess the risk of pre-eclampsia or pre-eclampsia-related conditions, and therefore identify risk subjects as early as possible. In particular, there is an urgent need to identify risk subjects before pre-eclampsia or pre-eclampsia-related conditions occur in subjects. Early identification will allow early start of appropriate patient management measures for the purpose of addressing this risk. Therefore, a reliable and sensitive biomarker is needed to assess the risk.

[0017] The technical problem on which the present invention is based can be seen as providing means and methods for meeting the above-mentioned needs. This technical problem is solved by the claims and the embodiments characterized in the following.

[0018] In the context of the present studies it was found that the measurement of the amount of IGFBP-7 in samples from pregnant subjects allows for a rapid and reliable prediction of pre-eclampsia or pre-eclampsia-related disorders (eg eclampsia, or HELLP syndrome).

[0019] Therefore, the present invention relates to a method for assessing whether a pregnant subject is at risk of developing pre-eclampsia or a pre-eclampsia-related condition, the method comprising the following steps:

[0020] (a) determining the amount of the biomarker IGFBP-7 (insulin-like growth factor binding protein 7) in a sample from a subject, and

[0021] (b) The amount of the determined biomarker is compared with a reference.

[0022] In an embodiment of the present invention, the risk of pre-eclampsia or a pre-eclampsia-related condition is assessed by performing a further step (c), wherein the further step (c) is to assess whether the pregnant subject is at risk of developing pre-eclampsia or a pre-eclampsia-related condition. The assessment should be based on the results of the comparison performed in step (b).

[0023] The method of the present invention is preferably an in vitro method. Moreover, in addition to those steps explicitly mentioned above, it may also include other steps. For example, further steps may involve sample pretreatment or evaluation of the results obtained by the method. The method of the present invention may also be used to monitor subjects, confirm subjects and subclassify subjects. The method may be implemented manually or assisted by automation. Preferably, steps (a), (b) and / or (c) may be assisted in whole or in part by automation, for example, by suitable robots and sensory equipment for the determination in step (a) or computer-implemented calculations in step (b).

[0024] According to the present invention, the risk of pre-eclampsia or a pre-eclampsia-related disorder in a pregnant subject should be assessed.Pre-eclampsia or a pre-eclampsia-related disorder are well known in the art.

[0025] As used herein, the term "pre-eclampsia" refers to a medical condition characterized by hypertension and proteinuria. Pre-eclampsia occurs in pregnant female subjects, and hypertension in this case is also referred to as pregnancy-induced hypertension. Preferably, pregnancy-induced hypertension is identified to be present in a subject by twice 140mmHg (systolic pressure) and / or 90mmHg (diastolic pressure) or higher blood pressure measurements, wherein the two measurements are made at least 6 hours apart. Proteinuria can be identified by 300 mg protein or more in a 24-hour urine sample. In addition, proteinuria can be identified by protein dipstick analysis (if ≥2+) (if ≥30mg / dL protein is present in a single urine sample), or by protein / creatinine ratio ≥30mg / mmol protein / creatinine in a single urine.

[0026] Pre-eclampsia according to the present invention can be a mild form or a severe form of pre-eclampsia. The terms "mild pre-eclampsia" and "severe pre-eclampsia" are well known in the art. The term "mild pre-eclampsia" preferably refers to proteinuria and hypertension (especially hypertension with blood pressure ≥140 / 90 mmHg) occurring twice at least 6 hours apart, but there is no evidence of end-organ damage in women with normal blood pressure before the 20th week of pregnancy. The term "severe pre-eclampsia" refers to pre-eclampsia with at least one of the following symptoms: systolic blood pressure of 160 mmHg or higher or diastolic blood pressure of 110 mmHg or higher twice at least 6 hours apart, proteinuria greater than 5 g in 24-hour collection, or more than 3+ in 2 random urine samples collected at least 4 hours apart, oliguria (especially less than 400 mL of urine in 24 hours), persistent headache, upper abdominal pain and / or liver function damage, and thrombocytopenia.

[0027] The studies implemented in the context of the present invention show that both the risk of early-onset pre-eclampsia and the risk of late-onset pre-eclampsia can be assessed. In particular, the assessment of the risk of a subject suffering from early-onset pre-eclampsia is advantageous because it is usually associated with more severe side effects and adverse outcomes compared to late-onset pre-eclampsia, which is usually relatively mild.

[0028] Thus, in an embodiment, the methods of the invention include assessing a subject's risk of having early-onset pre-eclampsia. Early-onset pre-eclampsia occurs between about the 20th week and about the 34th week of pregnancy. Thus, it is contemplated that a sample is obtained between about the 20th week and about the 34th week of pregnancy.

[0029] Thus, in another embodiment, the method of the invention comprises assessing the risk of a subject having late-onset pre-eclampsia. Late-onset pre-eclampsia occurs after the 34th week of gestation. Thus, it is contemplated that a sample is obtained after the 34th week of gestation.

[0030] The pre-eclampsia-related disorder is preferably selected from eclampsia and HELLP syndrome.

[0031] Eclampsia is a life-threatening disease characterized by the presence of tonic-clonic seizures or coma. Symptoms associated with severe pre-eclampsia are oliguria of less than 500 ml in 24 hours, cerebral or visual disturbances, pulmonary edema or cyanosis, epigastric or right upper quadrant pain, liver damage, thrombocytopenia.

[0032] The term "HELLP syndrome" is well known in the art. HELLP syndrome is a life-threatening obstetric complication that is generally considered a complication of pre-eclampsia. HELLP syndrome usually occurs during the third trimester of pregnancy. HELLP syndrome is associated with a high risk of adverse outcomes such as renal failure, subcapsular liver hematoma, recurrent eclampsia, or even death. "HELLP" is an abbreviation for the three main features of the syndrome: hemolysis, elevated liver enzymes, and low platelet counts. HELLP syndrome can be difficult to diagnose due to the variability of symptoms between patients (usually, patients have no symptoms other than general abdominal pain), and early diagnosis is key to reducing morbidity. If left untreated, patients may become seriously ill or die due to liver rupture / bleeding or cerebral edema. In patients who may have HELLP syndrome, a series of blood tests are performed: complete blood count, coagulation panel, liver enzymes, electrolytes, and renal function studies. Typically, fibrin degradation product (FDP) levels are determined, which may be elevated. Lactate dehydrogenase is a marker of hemolysis and is elevated (>600 U / liter).

[0033] According to the present invention, it should be assessed whether a pregnant subject has a risk of developing pre-eclampsia or a pre-eclampsia-related condition. Therefore, it should be predicted that a pregnant subject has a risk of developing pre-eclampsia or a pre-eclampsia-related condition (i.e., suffering from pre-eclampsia or a pre-eclampsia-related condition in the future). Therefore, the prediction of the risk of developing pre-eclampsia or a pre-eclampsia-related condition does not refer to the diagnosis of the patient currently suffering from pre-eclampsia or a pre-eclampsia-related condition, but refers to the risk of the patient having pre-eclampsia or a pre-eclampsia-related condition in the future. Therefore, it is envisioned that the subject to be tested will not suffer from the condition to be predicted, particularly at the time point at which the test sample has been obtained.

[0034] Preferably, the term "predicted risk" or "assessed risk" as used herein refers to the probability that the subject will suffer from pre-eclampsia or pre-eclampsia related conditions. In particular, the risk / probability predicted within a specific time window, for example. Within three days, one week, two weeks, three weeks, four weeks or six weeks. Therefore, it should be assessed whether the subject has a short-term risk. For example, a short-term risk is the risk of pre-eclampsia or pre-eclampsia related conditions occurring within a period of about one week to about four weeks. In addition, it is envisioned that a short-term risk is the risk of pre-eclampsia or pre-eclampsia related conditions occurring within a period of about one week to about two weeks.

[0035] In a preferred embodiment of the present invention, the prediction window is a period of one week. Therefore, it is assessed whether the subject has the risk of pre-eclampsia or pre-eclampsia related conditions occurring within one week. In another preferred embodiment of the present invention, the prediction window is a period of two weeks. In another preferred embodiment of the present invention, the prediction window is a period of three weeks. In another preferred embodiment of the present invention, the prediction window is a period of four weeks. Therefore, it is assessed whether the subject has the risk of pre-eclampsia or pre-eclampsia related conditions occurring within four weeks. Preferably, the prediction window is calculated according to the time point at which the sample to be tested has been obtained.

[0036] As will be appreciated by those skilled in the art, such prediction / assessment is generally not intended to be correct for 100% of subjects. The expression "predicted risk" generally requires that a statistically significant portion of a subject can be predicted / assessed in an appropriate and correct manner. Those skilled in the art can use various well-known statistical evaluation tools (e.g., determination of confidence intervals, determination of p-values, Student's t-tests, Mann-Whitney tests, etc.) to determine whether a portion is statistically significant without further effort. Detailed information is found in Statistics for Research, John Wiley & Sons, New York 1983 by Dowdy and Wearden. Preferred confidence intervals are at least 90%, at least 95%, at least 97%, at least 98% or at least 99%. The p-value is preferably 0.1, 0.05, 0.01, 0.005 or 0.0001. Preferably, the probability contemplated by the present invention allows at least 60%, at least 70%, at least 80% or at least 90% of the predictions for a given cohort or population of subjects to be correct.

[0037] Likewise, the expression "predicted risk" generally requires that for some subset of subjects (e.g., a cohort in a cohort study), the assessment is correct under the negative predictive value as described elsewhere herein. The risk of developing or not developing pre-eclampsia or a pre-eclampsia-related condition in a future time window can be diagnosed by a test such as the method of the present invention using summary statistics that describe the performance of the test relative to false positive / negative and true positive / negative assessments.

[0038] A higher negative predictive value indicates that the negative assessment made by the diagnostic test has a high confidence level. The negative predictive value can be expressed as the number of true negative results divided by the sum of true negative results and false negative results (i.e., all negative results determined by the diagnostic test). In principle, the negative predictive value can be calculated based on the sensitivity and specificity of the diagnostic test and the prevalence of the disease or condition in a certain cohort. Specifically, the negative predictive value is [(specificity) (1-prevalence)] / [(specificity) (1-prevalence) + (1-sensitivity) (prevalence)]. Prevalence predictions can be obtained from cohort studies, while case-control studies can derive the sensitivity and / or specificity of the test. In particular, the negative predictive value of the prediction established by the method of the present invention should be at least about 80%, at least about 85%, at least about 90%, more preferably at least about 92%, and, most preferably, at least about 94%. The aforementioned negative predictive value is, for example, applicable to a prediction window of one week.

[0039] The positive predictive value (PPV) is the percentage of subjects with a positive test who actually develop preeclampsia or a preeclampsia-related condition. The positive predictive value (PPV) is preferably at least about 20%, more preferably at least about 27%. The aforementioned negative predictive value is, for example, applicable to a four-week prediction window.

[0040] According to the present invention, the test subject is assigned to a subject group with a risk of pre-eclampsia or pre-eclampsia-related conditions, or to a subject group without a risk of pre-eclampsia or pre-eclampsia-related conditions. The subject with a risk of pre-eclampsia or pre-eclampsia-related conditions mentioned according to the present invention preferably indicates that the subject has an elevated risk (within the prediction window). Preferably, the elevated risk is compared to the average risk in the pregnant subjects of the same cohort. Therefore, the phrase "risk of pre-eclampsia or pre-eclampsia-related conditions" refers to a pregnant subject with a statistically significantly increased probability that pre-eclampsia or pre-eclampsia-related conditions will occur within the prognosis time window in the future compared to the pregnant subject without the risk of pre-eclampsia.

[0041] If the subject does not have the risk of developing pre-eclampsia or pre-eclampsia-related disorders as mentioned in the present invention, then preferably, the risk of developing pre-eclampsia or pre-eclampsia-related disorders (within the prediction window) is reduced. Preferably, the risk is reduced compared to the average risk in the subjects of the same cohort.

[0042] As mentioned herein, a "subject" is preferably a mammal. Mammals include, but are not limited to, domestic animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates, such as monkeys), rabbits, and rodents (e.g., mice and rats). Preferably, the subject is a human subject, i.e., a female human pregnant subject. The subject is preferably after the 19th week of pregnancy. In an embodiment, the pregnant subject is between about the 20th week and about the 40th week of pregnancy, particularly between about the 24th week and about the 40th week of pregnancy. In another embodiment, the pregnant subject is between about the 20th week and the 34th week of pregnancy, such as between about the 24th week and the 34th week of pregnancy. In another embodiment, the pregnant subject is between about the 34th week and about the 40th week of pregnancy.

[0043] In an embodiment of the present invention, the pregnant subject to be tested suffers from hypertension. In this case, hypertension is defined as two independent measurements of blood pressure of 140 mmHg (systolic pressure) and / or 90 mmHg (diastolic pressure) or higher, wherein the two measurements are made at least 6 hours apart. In an embodiment, the hypertension is new-onset hypertension. Therefore, it is envisaged that the pregnant subject should not have suffered from hypertension before pregnancy.

[0044] In an embodiment of the invention, the subject displays one or more of the following symptoms: new onset of elevated blood pressure, exacerbation of pre-existing hypertension, new onset of protein in the urine, exacerbation of pre-existing proteinuria, epigastric pain, excessive edema / severe swelling (face, hands, feet), headache, visual disturbances, sudden weight gain (e.g., more than 1 kg / week in late pregnancy), low platelets, elevated liver transaminases, intrauterine growth restriction (or suspected intrauterine growth restriction), abnormal uterine perfusion detected by Doppler ultrasound with a mean pulsatility index > 95% in mid-pregnancy, and bilateral uterine artery notching.

[0045] Furthermore, it is envisaged that the subject is a pregnant subject older than 40 years of age and / or a pregnant subject in her first pregnancy, a pregnant subject with a family history of pre-eclampsia (e.g. pre-eclampsia in the mother or sister), a pregnant subject with a previous history of pre-eclampsia in a previous pregnancy, a pregnant subject with a body mass index equal to or greater than 35 kg / m² at first contact, or a pregnant subject with multiple pregnancies or with a previous vascular disease (such as hypertension or diabetes), for example as described in NICE (National Institute for Health and Care Excellence, Antenatal Careguideline CG62, March 2008).

[0046] In another embodiment of the inventive method, the subject to be tested is a pregnant subject who is apparently healthy. In another embodiment, the test subject can be a pregnant subject who does not suffer from proteinuria. In another embodiment, the test subject can be a pregnant subject who does not suffer from hypertension. For such subjects, the method of the present invention can be used in conventional screening methods.

[0047] The term "sample" refers to a body fluid sample, a sample of separated cells or a sample from a tissue or organ. The body fluid sample can be obtained by well-known techniques and includes samples of the following items: blood, plasma, serum, urine, lymph, sputum, ascites or any other human secretion or its derivative. Preferred body fluid samples are urine, blood, serum or plasma. Tissue or organ samples can be obtained from any tissue or organ by, for example, biopsy. Separated cells can be obtained from body fluids or tissues or organs by separation techniques such as centrifugation or cell sorting. For example, cells, tissues or organ samples can be obtained from those cells, tissues or organs that express or produce biomarkers. The sample can be frozen, preserved, fixed (e.g., formalin fixed), centrifuged and / or embedded (e.g., paraffin embedded), etc. Of course, before the amount of markers in the assessment sample, the cell sample can be subjected to various well-known post-collection preparation and storage techniques (e.g., nucleic acid and / or protein extraction, fixation, storage, freezing, ultrafiltration, concentration, evaporation, centrifugation, etc.).

[0048] Furthermore, it is envisaged that the blood sample is a dried blood spot sample. A dried blood spot sample may be obtained by applying a drop of blood to an absorbent filter paper. The blood is allowed to completely saturate the paper and air dry for several hours. The blood may have been drawn from the subject to be tested (e.g., from a finger) by a lancet.

[0049] In a preferred embodiment, the sample is a blood (i.e., whole blood), serum, or plasma sample. Serum is the liquid portion of whole blood obtained after allowing the blood to clot. To obtain serum, the clot is removed by centrifugation and the supernatant is collected. Plasma is the cell-free fluid portion of blood. To obtain a plasma sample, whole blood is collected in a tube treated with an anticoagulant (e.g., a citrate-treated or EDTA-treated tube). Cells are removed from the sample by centrifugation, and a supernatant (i.e., a plasma sample) is obtained.

[0050] According to the invention, the amount of insulin-like growth factor binding protein 7 (= IGFBP-7) should be determined. Preferably, the amount of IGFBP-7 polypeptide is determined. IGFBP-7 is a 30 kDa modular glycoprotein, known to be secreted by endothelial cells, vascular smooth muscle cells, fibroblasts and epithelial cells (Ono, Y., et al., Biochem Biophys Res Comm 202 (1994) 1490-1496). Preferably, the term "IGFBP-7" refers to human IGFBP-7. The sequence of the protein is well known in the art and can be accessed, for example, via Uni-Prot (Q16270, IBP7_HUMAN) or via GenBank (NP_001240764.1). A detailed definition of the biomarker IGFBP-7 is provided, for example, in WO 2008 / 089994, which is incorporated herein by reference in its entirety. IGFBP-7 has two isoforms, isoform 1 and 2, which are produced by alternative splicing. In the present example, the total amount of both isoforms was determined (for the sequence, see UniProt database entries (Q16270-1 and Q16270-2)).

[0051] As used herein, the term "amount" encompasses the absolute amount of the biomarkers mentioned herein, the relative amount or concentration of the biomarkers, and any value or parameter associated therewith or derivable therefrom. Such values ​​or parameters include intensity signal values ​​from all specific physical or chemical properties obtained from the peptide by direct measurement, such as intensity values ​​in a mass spectrum or NMR spectrum. In addition, all values ​​or parameters obtained by indirect measurements specified elsewhere in this specification are encompassed, for example, the response amount determined from a biological readout system in response to a peptide or intensity signal obtained from a specifically bound ligand. It is to be understood that values ​​associated with the aforementioned amounts or parameters can also be obtained by all standard mathematical operations.

[0052] As referred to herein, the term "determining" the amount of a biomarker refers to quantification of the biomarker, such as determining the level of the biomarker in a sample using a suitable detection method as described elsewhere herein.

[0053] In an embodiment, the amount of a biomarker is determined by contacting a sample with a reagent that specifically binds to the biomarker, thereby forming a complex between the reagent and the biomarker, detecting the amount of the complex formed, and thereby determining the amount of the biomarker.

[0054] The biomarkers mentioned herein can be detected using methods generally known in the art. Detection methods generally include methods for quantifying the amount of biomarkers in a sample (quantitative methods). Technicians generally know which of the following methods are suitable for qualitative and / or quantitative detection of biomarkers. Proteins, for example, in samples can be conveniently measured using Western blotting (Westerns) and immunoassays (such as commercially available ELISA, RIA, fluorescence and luminescence-based immunoassays). Other suitable methods for detecting biomarkers include determining physical or chemical properties specific to a peptide or polypeptide, such as its precise molecular weight or NMR spectrum. The methods include, for example, biosensors, optical devices coupled to immunoassays, biochips, analytical equipment (such as mass spectrometers, NMR analyzers, or chromatographic equipment). In addition, each method includes a method based on microplate ELISA, a fully automatic or robotic immunoassay (e.g., in an Elecsys TM Analyzers), CBA (enzymatic cobalt binding assay, e.g., at Roche-Hitachi TM analyzers) and latex agglutination assays (e.g., available on Roche-Hitachi TM available on the analyzer).

[0055] For the detection of the biomarker proteins mentioned herein, a variety of immunoassay techniques using this assay format are available, see, for example, U.S. Pat. Nos. 4,016,043, 4,424,279, and 4,018,653. These include single-point and two-point or "sandwich" assays of non-competitive type, as well as traditional competitive binding assays. These assays also include direct binding of labeled antibodies to target biomarkers. Sandwich assays are one of the most useful immunoassays.

[0056] Methods employing electrochemiluminescent labeling are well known. Such methods utilize the ability of specific metal complexes to achieve an excited state by oxidation, from which they decompose to a ground state, emitting electrochemiluminescence. See Richter, MM, Chem. Rev. 104 (2004) 3003-3036 for a review.

[0057] In an embodiment, the detection antibody (or antigen binding fragment thereof) used to determine the amount of a biomarker is ruthenylated or iridinylated. Therefore, the antibody (or antigen binding fragment thereof) should include a ruthenium label. In an embodiment, the ruthenium label is a bipyridine-ruthenium (II) complex. Or the antibody (or antigen binding fragment thereof) should include an iridium label. In an embodiment, the iridium label is a complex disclosed in WO 2012 / 107419.

[0058] Determining the amount of a polypeptide (such as IGFBP-7) may preferably include the following steps: (a) contacting the polypeptide with an agent that specifically binds to the polypeptide, (b) (optionally) removing unbound agent, and (c) determining the amount of bound binding agent (i.e., the complex of the agent formed in step (a)). According to a preferred embodiment, the steps of contacting, optionally removing and determining may be performed by an analyzer unit. According to some embodiments, the steps may be performed by a single analyzer unit of the system or by more than one analyzer unit that are operably in communication with each other. For example, according to a specific embodiment, the system disclosed herein may include: a first analyzer unit for performing the steps of contacting and optionally removing; and a second analyzer unit operably connected to the first analyzer unit by a transport unit (e.g., a robotic arm), the second analyzer unit performing the step of determining.

[0059] The reagent (also referred to herein as "binding agent") that specifically binds to the biomarker can be covalently or non-covalently coupled to the label to allow detection and measurement of the bound agent. Labeling can be accomplished by direct or indirect methods. Direct labeling involves coupling the label directly (covalently or non-covalently) to the binding agent. Indirect labeling involves the binding of a second binding agent to a first binding agent (covalently or non-covalently). The second binding agent should specifically bind to the first binding agent. The second binding agent can be coupled to a suitable label and / or be the target (receptor) of a third binding agent that binds to the second binding agent. Suitable second and higher-order binding agents can include antibodies, second antibodies, and well-known binding systems, such as the streptavidin-biotin system (Vector Laboratories). The binding agent or substrate can also be "labeled" with one or more tags known in the art. Such a tag can then be the target of a higher-order binding agent. Suitable tags include biotin, digoxigenin, His tag, glutathione-S-transferase, FLAG, GFP, myc tag, influenza A virus hemagglutinin (HA), maltose binding protein, etc. In the case of a peptide or polypeptide, the tag is preferably at the N-terminus and / or C-terminus. Suitable labels are any labels that can be detected by a suitable detection method. Typical labels include gold particles, latex beads, 9,10-dihydroacridinium esters, luminol, ruthenium complexes, iridium complexes, enzyme activity labels, radioactive labels, magnetic labels ("such as magnetic beads", including paramagnetic and superparamagnetic labels) and fluorescent labels. Enzyme activity labels include, for example, horseradish peroxidase, alkaline phosphatase, β-galactosidase, luciferase and derivatives thereof. Suitable substrates for detection include diaminobenzidine (DAB), 3,3'-5,5'-tetramethylbenzidine, NBT-BCIP (4-nitro blue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate, available as a ready-made stock solution from Roche Diagnostics), CDP-Star™ (Amersham Bio-sciences), ECF™ (Amersham Biosciences). Suitable enzyme-substrate combinations can produce colored reaction products, fluorescence or chemiluminescence, which can be determined according to methods known in the art (e.g., using a photosensitive film or a suitable camera system). As for determining enzymatic reactions, the criteria given above apply similarly. Typical fluorescent labels include fluorescent proteins (such as GFP and its derivatives), Cy3, Cy5, Texas Red, fluorescein, and Alexa dyes (e.g., Alexa 568). Other fluorescent labels can be obtained, for example, from Molecular Probes (Oregon). It is also contemplated to use quantum dots as fluorescent labels. Radioactive labels can be detected by any known and appropriate method (e.g., photosensitive film or phosphor imager).

[0060] The amount of the polypeptide may also be preferably determined as follows: (a) a solid support comprising a binding agent for the polypeptide as described elsewhere herein is contacted with a sample comprising the peptide or polypeptide, and (b) the amount of the peptide or polypeptide bound to the support is determined. Materials for making supports are well known in the art and include, among others, commercially available column materials, polystyrene beads, latex beads, magnetic beads, colloidal metal particles, glass and / or silicon wafers and surfaces, nitrocellulose strips, membranes, sheets, duracytes, wells and walls of reaction trays, plastic tubes, and the like.

[0061] In another aspect, the sample is removed from the complex formed between the binding agent and a label before measuring the amount of the complex formed. Thus, in one aspect, the binding agent can be immobilized on a solid support. In another aspect, the sample can be removed from the complex formed on the solid support by applying a washing solution.

[0062] The "sandwich assay" is one of the most useful and commonly used assays that covers many variations of the sandwich assay technology. In short, in a typical assay, an unlabeled (captured) binding agent is fixed or can be fixed on a solid substrate, and the sample to be tested is contacted with the capture binding agent. After an appropriate incubation period, a second (detection) binding agent is then added and incubated for a period of time sufficient to allow the formation of a binding agent-biomarker complex, which is labeled with a reporter molecule capable of producing a detectable signal, thereby leaving enough time for the formation of another complex of the binding agent-biomarker-labeled binding agent. Optionally, any unreacted material can be washed away. The presence of a biomarker can be determined by observing the signal generated by the reporter molecule bound to the detection binding agent. The results can be qualitative by simple observation of the visible signal, or the results can be quantitatively compared with a control sample containing a known amount of biomarkers.

[0063] The incubation steps of a typical sandwich assay can vary according to need and circumstances. Such variations include, for example, simultaneous incubations, in which two or more binding agents and biomarkers are incubated together. For example, both the sample to be analyzed and the labeled binding agent are added to the immobilized capture binding agent at the same time. It is also possible to first incubate the sample to be analyzed and the labeled binding agent, and then add the antibody that is bound to the solid phase or capable of binding to the solid phase.

[0064] The complex formed between the specific binding agent and the biomarker should be proportional to the amount of the biomarker present in the sample. It will be understood that the specificity and / or sensitivity of the binding agent to be applied defines the degree of proportion of at least one marker that can be specifically bound included in the sample. Further details on how the measurement can be implemented are also found elsewhere in this article. The amount of the complex formed should be converted into the amount of the biomarker to reflect the amount that is actually present in the sample.

[0065] The terms "binding agent", "specific binding agent", "analyte-specific binding agent", "detection reagent" and "reagent that specifically binds to a biomarker" are used interchangeably herein. Preferably, it relates to a reagent that includes a binding portion that specifically binds to a corresponding biomarker. Examples of "binding agents" or "reagents" are nucleic acid probes, nucleic acid primers, DNA molecules, RNA molecules, aptamers, antibodies, antibody fragments, peptides, peptide nucleic acids (PNA) or compounds. Preferred reagents are antibodies or antigen-binding fragments thereof that specifically bind to the biomarker to be determined. The term "antibody" herein is used in the broadest sense and covers various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies) and antibody fragments, as long as they exhibit the desired antigen-binding activity (i.e., antigen-binding fragments thereof). Preferably, the antibody is a polyclonal antibody. More preferably, the antibody is a monoclonal antibody.

[0066] The term "specific binding" or "specifically binds" refers to a binding reaction in which the binding pair molecules exhibit binding to each other without significant binding to other molecules. When referring to proteins or peptides as biomarkers, the term "specific binding" or "specifically binds" refers to a binding reaction in which the binding agent binds to the target protein with a specific binding affinity of at least 10 -7 The term "specific binding" or "specifically binds" preferably means that the affinity for its target molecule is at least 10 -8 M, or even more preferably at least 10 -9 M. The term "specific" or "specifically" is used to indicate that other molecules present in the sample do not significantly bind to the binding agent specific for the target molecule.

[0067] As used herein, the term "comparison" refers to comparing the amount of a biomarker in a sample from a subject with a reference amount of a biomarker specified elsewhere in this specification. It should be understood that, as used herein, comparison generally refers to the comparison of corresponding parameters or values, for example, comparing an absolute amount with an absolute reference amount, and comparing a concentration with a reference concentration, or comparing an intensity signal obtained from a biomarker in a sample with an intensity signal of the same type obtained from a reference sample. The comparison can be implemented manually or computer-assisted. Therefore, the comparison can be implemented by a computing device. For example, the value of the amount of a biomarker determined or detected in a sample from a subject can be compared with a reference amount, and the comparison can be automatically implemented by an algorithm that performs the comparison by a computer program. The computer program implementing the assessment will provide the desired assessment in a suitable output format. For computer-assisted comparisons, the value of the determined amount can be compared with the value corresponding to a suitable reference stored in a database by a computer program. The computer program can further evaluate the result of the comparison, i.e., automatically provide the desired assessment in a suitable output format. For computer-assisted comparisons, the value of the determined amount can be compared with the value corresponding to a suitable reference stored in a database by a computer program. The computer program may further evaluate the results of the comparison, ie automatically provide the desired evaluation in a suitable output format.

[0068] According to the present invention, the amount of biomarker IGFBP-7 should be compared with a reference. The reference is preferably a reference amount. As used herein, the term "reference amount" refers to an amount that allows a subject to be assigned to one of the following: (i) a subject group suffering from pre-eclampsia or a pre-eclampsia-related condition or (ii) a subject group not suffering from pre-eclampsia or a pre-eclampsia-related condition. A suitable reference amount can be determined together with the test sample (i.e., simultaneously) or subsequently from a reference sample to be analyzed.

[0069] In principle, by applying standard statistical methods, a reference amount can be calculated for subjects of the same cohort specified above based on the average or mean of a given biomarker. In particular, the accuracy of tests such as methods intended to diagnose or not diagnose an event is best described by its receiver operating characteristic (ROC) (see especially Zweig 1993, Clin. Chem. 39: 561-577). The ROC graph is a plot of all sensitivity and specificity pairs obtained by constantly changing the decision threshold over the entire range of observed data. The clinical performance of a prognostic method depends on its accuracy, i.e., its ability to correctly assign subjects to a specific prognosis. The ROC plot represents the overlap between the two distributions by plotting the sensitivity and 1-specificity of the entire threshold range suitable for distinction. On the y-axis is the sensitivity or true positive score, which is defined as the ratio of the number of true positive test results to the product of the number of true positive test results and the number of false negative test results. In the presence of a disease or condition, this is also called positive. It is calculated only from the affected subgroup. On the x-axis is the false positive score or 1-specificity, which is defined as the ratio of the number of false positive results to the product of the number of true negative results and the number of false positive results. It is an indicator of specificity and is calculated entirely from the unaffected subgroup. Since the true and false positive scores are calculated completely separately by using the test results from two different subgroups, the ROC plot is independent of the prevalence of the event in the same cohort. Each point on the ROC plot represents a sensitivity / 1-specificity pair corresponding to a specific decision threshold. The ROC plot for a test with perfect discrimination (no overlap in the two result distributions) passes through the upper left corner, where the true positive score is 1.0 or 100% (perfect sensitivity) and the false positive score is 0 (perfect specificity). The theoretical plot for a test without discrimination (the same result distribution for both groups) is a 45° diagonal line from the lower left corner to the upper right corner. Most plots fall between these two extremes. If the ROC plot falls completely below the 45° diagonal, this is easily solved by flipping the criterion for "positive" from "greater than" to "less than" or vice versa. Qualitatively, the closer drawing is to the upper left corner, the higher the overall accuracy of the test. According to the expected confidence interval, a threshold value can be derived from the ROC curve, so as to allow the appropriate balance of sensitivity and specificity to be used to diagnose a given event. Therefore, a reference for the aforementioned method of the present invention can be generated, i.e., a threshold value, which allows the subject with the risk of suffering from pre-eclampsia or pre-eclampsia related conditions or the subject without the risk of suffering from pre-eclampsia or pre-eclampsia related conditions to be distinguished among the pregnant subjects of the same period group, preferably, this is achieved by setting up ROC for the same period group as described above and deriving a threshold amount therefrom. According to the sensitivity and specificity desired by the diagnostic method, the ROC drawing allows to derive a suitable threshold value.It will be appreciated that optimal sensitivity is desired to remove subjects at risk for having pre-eclampsia or a pre-eclampsia-related condition (ie, exclusion), whereas optimal specificity is envisioned for subjects assessed as being at risk for having pre-eclampsia or a pre-eclampsia-related condition (ie, inclusion).

[0070] In certain embodiments, the term "reference amount" herein refers to a predetermined value. The predetermined value should allow for differentiation between subjects at risk of developing pre-eclampsia or a pre-eclampsia-related disorder and subjects not at risk of developing pre-eclampsia or a pre-eclampsia-related disorder.

[0071] In an embodiment of the present invention, the reference amount should allow for excluding the risk of suffering from pre-eclampsia or pre-eclampsia-related disorders, for example, within a four-week prediction window. An amount of IGFBP-7 below the reference amount generally indicates a subject who does not have the risk of suffering from pre-eclampsia or pre-eclampsia-related disorders, for example, within a four-week prediction window.

[0072] In an embodiment of the present invention, the reference amount should allow for inclusion of, for example, a risk of suffering from pre-eclampsia or a pre-eclampsia-related disorder within a one-week prediction window. An amount of IGFBP-7 above the reference amount is generally indicative of a subject at risk of suffering from pre-eclampsia or a pre-eclampsia-related disorder within a one-week prediction window.

[0073] The following applies as a diagnostic algorithm.

[0074] Preferably, an amount of IGFBP-7 in a sample of a test subject that is equal to or higher than the reference amount indicates that the subject is at risk of suffering from pre-eclampsia or a pre-eclampsia-related disorder. Also preferably, an amount of IGFBP-7 in a sample that is lower than the reference amount indicates that the subject is not at risk of suffering from pre-eclampsia and / or a pre-eclampsia-related disorder.

[0075] In an embodiment, the reference amount is derived from a pregnant subject or a group of pregnant subjects known to be not at risk for pre-eclampsia or a pre-eclampsia-related condition. Preferably, the reference amount is derived from a pregnant subject or a group of pregnant subjects at the same gestational stage (e.g., trimester, month or week) as the subject to be tested. Preferably, a decrease in the amount of biomarker IGFBP-7 in the test subject sample compared to the reference amount or the same as the reference amount indicates that the subject is not at risk for pre-eclampsia or a pre-eclampsia-related condition.

[0076] In an embodiment, the reference amount is derived from a pregnant subject or a group of pregnant subjects known to be at risk for pre-eclampsia or a pre-eclampsia-related condition. Preferably, the reference amount is derived from a pregnant subject or a group of pregnant subjects at the same gestational stage (e.g., trimester, month or week) as the subject to be tested. Preferably, an increase in the amount of the biomarker IGFBP-7 in the test subject sample compared to the reference amount or the same as the reference amount indicates that the subject is at risk for pre-eclampsia or a pre-eclampsia-related condition.

[0077] As used herein, "reference" generally refers to a reference amount or value representing the following: a cutoff value for making a prediction with a negative predictive value of at least about 80%, at least about 85%, at least about 90%, more preferably at least about 92%, or most preferably at least about 94%. In an embodiment, the prediction is made within a window period of one week.

[0078] In addition, "reference" as used herein may refer to a reference amount or value representing the following: a cutoff value for making a prediction with a positive predictive value of at least about 20%, more preferably at least about 27%, or most preferably at least about 27%. In an embodiment, the prediction is made within a four-week window period.

[0079] In an embodiment, the reference amount is in the range of about 90 to 110 ng / ml, in particular 90 to 105 ng / ml.

[0080] In an embodiment, the reference amount is an amount of about 100 to 105 ng / ml, such as an amount of 102 to 105 ng / ml, for example 104 ng / ml. Such an amount will, for example, allow for inclusion of the risk. Thus, an amount of IGFBP-7 above the reference amount indicates that the subject is at risk of suffering from pre-eclampsia or a pre-eclampsia-related disorder, for example within a period of one week.

[0081] In another embodiment, the reference amount is an amount of about 95 to 99.9 ng / ml, such as an amount of 96 to 97 ng / ml, for example 97 ng / ml. Such an amount will, for example, allow the risk to be excluded. Therefore, an amount of IGFBP-7 below the reference amount indicates that the subject is not at risk of suffering from pre-eclampsia or a pre-eclampsia-related disorder, for example, within a period of four weeks.

[0082] Therefore, it is also envisaged to use reference amounts that allow the inclusion of said risks and / or reference amounts for excluding risks.

[0083] In another preferred embodiment of the method of the present invention, the method further comprises recommending or initiating patient management measures based on the evaluation made by the method of the present invention.

[0084] As used herein, the term "recommendation" refers to establishing a suggestion that may be applied to a subject or may not be applied to a subject for patient management measures or its combination. However, in a specific embodiment, it should be understood that the term does not include application of actual management measures. As used herein, patient management measures refer to all measures applicable to a subject suffering from pre-eclampsia in order to cure, avoid or dispose of health conditions. For example, patient management measures include the degree of monitoring (for example, close, regular or weak monitoring), hospitalization or ambulatory maintenance, application of drug therapy or no drug therapy or lifestyle recommendation. Preferably, if the subject is assessed as having the risk of pre-eclampsia or pre-eclampsia related conditions occurring, the patient management measures are selected from the group of following measures: close monitoring, hospitalization, administration of hypotensive agents and lifestyle recommendation. Preferably, if the subject is assessed as not having the risk of pre-eclampsia occurring, the patient management measures are ambulatory monitoring.

[0085] In an embodiment, the blood pressure lowering agent is selected from the group consisting of methyldopa, labetalol and nifedipine.

[0086] Furthermore, the present invention contemplates the use of the biomarker IGFBP-7 or at least one detection reagent that specifically binds to IGFBP-7 in vitro in a sample of a pregnant subject to assess whether the subject is at risk for developing pre-eclampsia or a pre-eclampsia-related condition. The term "detection reagent" has been defined elsewhere herein. In an embodiment, the detection reagent is an antibody or antigen-binding fragment thereof that specifically binds to IGFBP-7.

[0087] The definitions and explanations given above apply mutatis mutandis to the following embodiments of the present invention.

[0088] The present invention also relates to a method for distinguishing between a pregnant subject at risk of developing pre-eclampsia or a pre-eclampsia-related condition and a pregnant subject not at risk of developing pre-eclampsia or a pre-eclampsia-related condition, the method comprising the steps of

[0089] (a) determining the amount of the biomarker IGFBP-7 (insulin-like growth factor binding protein 7) in a sample from a subject, and

[0090] (b) The amount of the determined biomarker is compared with a reference.

[0091] The aforementioned method may further comprise step c): distinguishing between pregnant subjects at risk of developing pre-eclampsia or a pre-eclampsia-related disorder and pregnant subjects not at risk of developing pre-eclampsia or a pre-eclampsia-related disorder based on the results of comparing step b).

[0092] Likewise, the present invention contemplates the use in vitro of the biomarker IGFBP-7 or at least one detection reagent that specifically binds to IGFBP-7 in a sample from a pregnant subject to distinguish between pregnant subjects at risk of developing pre-eclampsia or a pre-eclampsia-related condition and pregnant subjects not at risk of developing pre-eclampsia or a pre-eclampsia-related condition.

[0093] The present invention also relates to a computer-implemented method for assessing whether a pregnant subject is at risk for developing pre-eclampsia or a pre-eclampsia-related condition, the method comprising:

[0094] (a) receiving at a processing unit a value of the amount of IGFBP-7 determined in a sample from a pregnant subject,

[0095] (b) comparing, by the processing unit, the value received in step (a) with a reference for IGFBP-7, and

[0096] (c) Assessing whether pregnant subjects are at risk of developing pre-eclampsia or pre-eclampsia-related conditions.

[0097] The above method is a computer-implemented method. Preferably, all steps of the computer-implemented method are performed by one or more processing units of a computer (or computer network). Therefore, the evaluation in step (c) is performed by the processing unit. Preferably, the evaluation is based on the result of step (b).

[0098] As described elsewhere herein, the value received in step (a) should be derived from a determination of the amount of IGFBP-7 in a sample from a pregnant subject. Preferably, the value is a value for the concentration of IGFBP-7. The value will typically be received by the processing unit by uploading or sending the value to the processing unit. Alternatively, the processing unit may receive the value by inputting the value via a user interface.

[0099] In an embodiment of the aforementioned method, the reference mentioned in step (b) is established from a memory. Preferably, the value for the reference is established from a memory.

[0100] In an embodiment of the above-described computer-implemented method of the invention, the result of the evaluation made in step c) is provided via a display configured to present the result.

[0101] In an embodiment of the above-described computer-implemented method of the present invention, the method may comprise the further step of transmitting information about the assessment made in step c) to an electronic medical record of the individual.

[0102] The present invention also relates to a computer program comprising computer executable instructions for performing the steps of a computer-implemented method for assessing whether a pregnant subject is at risk of developing pre-eclampsia or a pre-eclampsia-related condition according to the present invention when the program is executed on a computer or a computer network. In general, the computer program may specifically comprise computer executable instructions for performing the steps of the method disclosed herein. In particular, the computer program may be stored on a computer readable data carrier.

[0103] The present invention also contemplates a method of aiding in assessing whether a pregnant subject is at risk for developing pre-eclampsia or a pre-eclampsia-related condition, the method comprising the steps of:

[0104] (a) receiving a sample obtained from said pregnant subject,

[0105] (b) determining the amount of the biomarker IGFBP-7 in the sample, and

[0106] (c) providing information regarding the value of the determined amount of the biomarker IGFBP-7 to a physician to assist in assessing whether a pregnant subject is at risk for developing pre-eclampsia or a pre-eclampsia-related disorder.

[0107] The physician should be the physician who requests the determination of the biomarker IGFBP-7 for risk prediction, i.e., the physician is the attending physician. The physician should treat the pregnant subject. The aforementioned method should help the attending physician assess whether the pregnant subject is at risk of developing pre-eclampsia or pre-eclampsia-related conditions.

[0108] In an embodiment of the foregoing method, step a) of receiving a sample does not include extracting a sample from a subject. Instead, a sample that has been obtained from a subject (e.g., under the supervision of an attending physician) is provided. For example, the sample can be provided by delivering the sample to a laboratory that performs the determination of the amount of biomarker IGFBP-7 in the sample.

[0109] After determining the amount, information about the value of the determined amount is provided to the physician. In addition, information about the value of the reference amount can be provided. The information provided can further include an indication of whether the pregnant subject has a risk of developing pre-eclampsia or a pre-eclampsia-related condition.

[0110] The present invention also relates to a device adapted to assess whether a pregnant subject is at risk of developing pre-eclampsia or a pre-eclampsia-related condition, the device comprising:

[0111] (a) an analytical unit comprising at least one detection reagent that specifically binds to the biomarker IGFBP-7, said unit being adapted to determine the amount of said biomarker in a sample from a pregnant subject; and

[0112] (b) an evaluation unit comprising a data processor, said evaluation unit having implemented an algorithm for comparing said amount with a reference, thereby evaluating whether the pregnant subject is at risk of developing pre-eclampsia or a pre-eclampsia-related condition.

[0113] The method of the present invention can be implemented by the aforementioned device. Therefore, the device should be adapted to perform the method of the present invention. The device as used herein should include at least the aforementioned unit. The various units of the device are operably linked to each other. How to link these units in an operational manner will depend on the type of unit included in the device. For example, in the case where a device for automatic quantitative measurement of IGFBP-7 is applied in an analysis unit, the data obtained by the automatic operation unit can be processed by an evaluation unit (e.g., by a computer program running on a computer as a data processor) to facilitate diagnosis. In an embodiment, the data processor performs a comparison of the amount of the biomarker with a reference.

[0114] Preferably, in this case, these units are included in a single device. However, the analysis unit and the evaluation unit can also be physically separated. In this case, the operable link can be achieved via wired and wireless connections that allow data transmission between the units. The wireless connection can use a wireless local area network (WLAN) or the Internet. The wired connection can be achieved by optical and non-optical cable connections between the units. The cable used for the wired connection is preferably suitable for high-throughput data transmission.

[0115] A preferred analytical unit for determining IGFBP-7 comprises a reagent that specifically recognizes IGFBP-7, such as an antibody (or an antigen binding fragment thereof), as described elsewhere herein, and an area for contacting the detection reagent with the sample to be tested. The reagent may be fixed to the area for contact, or the reagent may be applied to the area after loading the sample. Preferably, the analytical unit should be adapted to quantitatively determine the amount of the complex of the reagent and IGFBP-7.

[0116] In a preferred embodiment of the device of the present invention, the stored reference is a predetermined value (as described elsewhere herein). Preferably, an amount of the biomarker IGFBP-7 above the reference amount indicates that the subject is at risk of having pre-eclampsia or a pre-eclampsia-related disorder. Preferably, an amount of the biomarker IGFBP-7 below the reference amount indicates that the subject is not at risk of having pre-eclampsia or a pre-eclampsia-related disorder.

[0117] In another preferred embodiment of the device of the present invention, the stored reference is a reference amount derived from a subject or a group of subjects known not to be at risk of pre-eclampsia or a pre-eclampsia-related disorder, or a reference amount derived from a subject or a group of subjects known to be at risk of pre-eclampsia or a pre-eclampsia-related disorder.

[0118] The entire disclosure contents of all references cited in the present specification and the disclosure contents specifically mentioned in the present specification are incorporated herein by reference.

[0119] The accompanying drawings show:

[0120] Figure 1 Figure : Boxplot of IGFBP-7 levels [ng / mL] in pregnant women divided by control group (no PE = no preeclampsia; n = 354) and PE (preeclampsia; n = 27) diagnosis group within one week. The bottom and top edges of each box represent the first and third quartiles, respectively, the band within the box represents the median value, and the whiskers represent the value 1.5 times the interquartile range. The mean serum IGFBP-7 value was increased in pregnant women diagnosed with preeclampsia within one week (PE) compared with women not diagnosed with preeclampsia within one week (no PE = control group). The diagnosis of preeclampsia was defined as new-onset hypertension and proteinuria after the 20th week of pregnancy.

[0121] Figure 2 Figure : Boxplot of IGFBP-7 levels [ng / mL] in pregnant women divided by the control group (no PE = no pre-eclampsia; n = 328) and the PE (pre-eclampsia; n = 53) diagnosis group within four weeks. The bottom and top edges of each box represent the first and third quartiles, respectively, the band within the box represents the median value, and the whiskers represent the value 1.5 times the interquartile range. The mean serum IGFBP-7 was increased in pregnant women with new-onset pre-eclampsia within four weeks (PE) compared with women without new-onset pre-eclampsia within four weeks (no PE = control group).

[0122] Figure 3 Figure : Boxplot of IGFBP-7 levels [ng / mL] in pregnant women divided by diagnosis of control group (no PE = no pre-eclampsia; n = 305) and PE (pre-eclampsia; n = 76) during pregnancy until delivery (overall diagnosis). The bottom and top edges of each box represent the first and third quartiles, respectively, the band within the box represents the median value, and the whiskers represent values ​​1.5 times the interquartile range. The mean serum IGFBP-7 level was increased in pregnant women diagnosed with pre-eclampsia during pregnancy (PE) compared with women not diagnosed with pre-eclampsia during pregnancy (no PE = control group).

[0123] Figure 4: Receiver operator characteristic (ROC) curve of IGFBP-7 for predicting pre-eclampsia within one week. The ROC curve of serum IGFBP-7 for discriminating pregnant women who developed pre-eclampsia within one week from those who did not, resulted in an area under the curve (AUC) of 77.8% (95% confidence interval, 69.1-86.5).

[0124] Figure 5 : ROC (Receiver Operator Characteristic) curve of IGFBP-7 for predicting pre-eclampsia within four weeks. The ROC curve of serum IGFBP-7 for distinguishing pregnant women who developed pre-eclampsia within four weeks from those who did not showed an area under the curve (AUC) of 78.7% (95% confidence interval 72.6-84.8).

[0125] Example

[0126] The present invention will be merely illustrated by the following examples which should not be interpreted in any way as limiting the scope of the present invention.

[0127] Example 1: Predicting preeclampsia in pregnant women within one week by determining the level of IGFBP-7 in maternal serum or plasma

[0128] The Elecsys IGFBP-7 immunoassay has been developed for the fully automated quantification of the analyte IGFBP-7 in serum or plasma on the cobas® platform (Roche Diagnostics).

[0129] Figure 1 Shown are box plots of IGFBP-7 levels [ng / mL] in pregnant women divided by control group (no PE = no preeclampsia; n = 354) and PE (preeclampsia; n = 27) diagnosis group within one week. The box plots show that the mean serum IGFBP-7 was increased in pregnant women diagnosed with preeclampsia within one week (PE; mean IGFBP-7 = 110.90 ng / mL) compared with women not diagnosed with preeclampsia within one week (no PE = control group; mean IGFBP-7 = 95.24 ng / mL). The diagnosis of preeclampsia was defined as new-onset hypertension and proteinuria after the 20th week of pregnancy.

[0130] Table 1: Maternal serum IGFBP-7 levels [ng / mL] by control group (no PE) and preeclampsia (PE) within one week.

[0131] Minimum Qu.-05 Qu.-25 median Qu.-75 Qu.-95 maximum average SD IQR Total N No PE within 1 week (n = 354) 44.73 73.53 83.77 92.66 102.01 122.88 269.79 95.24 21.22 18.24 354 PE within 1 week (n=27) 77.55 89.36 99.51 107.81 120.66 143.61 174.22 110.90 19.17 21.15 27

[0132] Figure 4 The ROC (receiver operator characteristic) curve of IGFBP-7 for predicting pre-eclampsia within one week is shown. The ROC curve of serum IGFBP-7 for distinguishing pregnant women who developed pre-eclampsia within one week from those who did not develop pre-eclampsia within one week resulted in an area under the curve (AUC) of 77.8% (95% confidence interval, 69.1-86.5).

[0133] Table 2: Summary of ROC curves / area under the curve (AUC) for prediction of pre-eclampsia within one week.

[0134] AUC Lower 95% CI Upper 95% CI PE forecast within one week 77.8% 69.1% 86.5%

[0135] Table 3 shows that the negative predictive value (NPV) for excluding preeclampsia within one week using an IGFBP-7 cutoff of 104.1 ng / mL (maximum sensitivity with a specificity of at least 80%) was 96.6% (95% CI 93.8-98.4), with a sensitivity of 63.0% and a specificity of 80.2% / mL.

[0136] Table 3: Summary of the predictive performance of maternal serum IGFBP-7 for predicting pre-eclampsia within one week using an IGFBP-7 cutoff value of 104.1 ng / mL.

[0137] Estimated value 95% CI count NPV 96.6% 93.8; 98.4 284 / 294 PPV 19.5% 11.8; 29.4 17 / 87 Sensitivity 63.0% 42.4; 80.6 17 / 27 Specificity 80.2% 75.7; 84.2 284 / 354

[0138] Example 2: Prediction of preeclampsia in pregnant women within four weeks by determining the level of IGFBP-7 in maternal serum or plasma

[0139] Figure 2 Shown are box plots of IGFBP-7 levels [ng / mL] in pregnant women divided by control group (no PE = no preeclampsia; n = 328) and PE (preeclampsia; n = 53) diagnosis group within four weeks. The box plots show that the mean serum IGFBP-7 was increased in pregnant women diagnosed with preeclampsia within one week (PE; mean IGFBP-7 = 108.75 ng / mL) compared with women not diagnosed with preeclampsia within one week (no PE = control group; mean IGFBP-7 = 94.34 ng / mL). The diagnosis of preeclampsia was defined as new-onset hypertension and proteinuria after the 20th week of pregnancy.

[0140] Table 4: Maternal serum IGFBP-7 levels [ng / mL] by control group (no PE) and pre-eclampsia (PE) over four weeks.

[0141] Minimum Qu.-05 Qu.-25 median Qu.-75 Qu.-95 maximum average SD IQR Total N No PE within 4 weeks (n=328) 44.73 72.22 83.50 91.84 100.33 119.86 269.79 94.34 21.51 16.83 328 PE within 4 weeks (n=53) 77.55 86.50 98.71 106.94 120.34 132.76 174.22 108.75 16.40 21.63 53

[0142] Figure 5 The ROC (receiver operator characteristic) curve of IGFBP-7 for predicting pre-eclampsia within four weeks is shown. The ROC curve of serum IGFBP-7 for distinguishing pregnant women who developed pre-eclampsia within four weeks from those who did not develop pre-eclampsia within four weeks resulted in an area under the curve (AUC) of 78.7% (95% confidence interval, 72.6-84.8).

[0143] Table 5: Summary of ROC curves / area under the curve (AUC) for prediction of pre-eclampsia within four weeks.

[0144] AUC Lower 95% CI Upper 95% CI PE forecast within four weeks 78.7% 72.6% 84.8%

[0145] Table 6 shows that the negative predictive value (NPV) for excluding pre-eclampsia within four weeks using an IGFBP-7 cutoff of 97.6 ng / mL (maximum specificity with a sensitivity of at least 75%) was 94.4% (95% CI 90.7-97.0), with a sensitivity of 75.5% and a specificity of 67.4% / mL.

[0146] Table 6: Summary table of the predictive performance of maternal serum IGFBP-7 for predicting pre-eclampsia within four weeks using an IGFBP-7 cutoff value of 97.6 ng / mL.

[0147] Estimated value 95% CI count NPV 94.4% 90.7; 97.0 221 / 234 PPV 27.2% 20.2; 35.2 40 / 147 Sensitivity 75.5% 61.7; 86.2 40 / 53 Specificity 67.4% 62.0; 72.4 221 / 328

Claims

1. Use of i) the biomarker IGFBP-7 (insulin-like growth factor binding protein 7) or ii) an agent that specifically binds to IGFBP-7 in the manufacture of a kit for assessing whether a pregnant subject is at risk of developing pre-eclampsia by the following method, the method comprising the following steps: (a) determining the amount of the biomarker IGFBP-7 in a sample from the subject, and (b) Comparison of the amount of the determined biomarker with a reference.

2. The use according to claim 1, wherein The sample is a body fluid.

3. The use according to claim 1, wherein The sample is blood, serum or plasma.

4. The use according to claim 1 or 2, wherein the subject is a human subject and / or wherein the subject suffers from hypertension.

5. The use according to claim 1 or 2, wherein pre-eclampsia is early-onset pre-eclampsia or late-onset pre-eclampsia.

6. The use according to claim 1 or 2, wherein The risk to be assessed is the short-term risk, which is the risk of developing pre-eclampsia over a period of one week.

7. The use according to claim 1 or 2, wherein The risk to be assessed is the short-term risk, which is the risk of developing pre-eclampsia over a four-week period.

8. The use according to claim 6, wherein One-week periods were used to place patients into risk groups with increased risk of pre-eclampsia within a certain time window.

9. The use according to claim 7, wherein: The four-week period is used to exclude patients from risk groups with increased risk of pre-eclampsia within a certain time window.

10. The use according to claim 1 or 2, wherein the pregnant subject is after the 19th week of pregnancy.

11. The method of claim 1 or 2, further comprising recommending patient management measures based on the assessment, wherein (i) if the subject has been assessed as being at risk for developing pre-eclampsia, the patient management measure is selected from the group consisting of: close monitoring, hospitalization, administration of antihypertensive agents, and lifestyle recommendations, and (ii) if the subject has been assessed as not being at risk for developing pre-eclampsia, the patient management measure is ambulatory monitoring.

12. A computer-implemented method for assessing whether a pregnant subject is at risk for developing pre-eclampsia, the method comprising: (a) receiving at a processing unit a value of the amount of IGFBP-7 determined in a sample from a pregnant subject, (b) comparing, by the processing unit, the value received in step (a) with a reference for IGFBP-7, and (c) To assess whether pregnant subjects are at risk for developing pre-eclampsia. The method of claim 12 , wherein the reference is established from a memory.

14. Use of i) the biomarker IGFBP-7 (insulin-like growth factor binding protein 7) or ii) an agent that specifically binds to IGFBP-7 in the manufacture of a kit for helping to assess whether a pregnant subject is at risk of developing pre-eclampsia by the following method, the method comprising the following steps: (a) receiving a sample obtained from said pregnant subject, (b) determining the amount of the biomarker IGFBP-7 in the sample, and (c) providing information to a physician regarding the value of the determined amount of the biomarker IGFBP-7, thereby assisting in assessing whether a pregnant subject is at risk of developing pre-eclampsia.

15. Use of i) the biomarker IGFBP-7 (insulin-like growth factor binding protein 7) or ii) an agent that specifically binds to IGFBP-7 in the manufacture of a kit for distinguishing between pregnant subjects at risk of developing pre-eclampsia and pregnant subjects not at risk of developing pre-eclampsia by the following method, the method comprising the following steps: (a) determining the amount of the biomarker IGFBP-7 in a sample from the subject, and (b) Comparison of the amount of the determined biomarker with a reference.

16. A computer-implemented method for facilitating the assessment of whether a pregnant subject is at risk for developing pre-eclampsia, the method comprising the steps of: (a) receiving the amount of the biomarker IGFBP-7 (insulin-like growth factor binding protein 7) determined in a sample from said subject, and (c) providing information to a physician regarding the value of the determined amount of the biomarker IGFBP-7, thereby assisting in assessing whether a pregnant subject is at risk of developing pre-eclampsia.

17. A computer-implemented method for distinguishing between pregnant subjects at risk of developing pre-eclampsia and pregnant subjects not at risk of developing pre-eclampsia, the method comprising the steps of: (a) receiving the amount of the biomarker IGFBP-7 (insulin-like growth factor binding protein 7) determined in a sample from a subject, and (b) Comparison of the amount of the determined biomarker with a reference.

18. The method of any one of claims 12, 16 or 17, wherein the subject does not suffer from pre-eclampsia.

19. Use of the biomarker IGFBP-7 or at least one detection agent that specifically binds to IGFBP-7 in the manufacture of a kit for assessing whether a pregnant subject has a risk of developing pre-eclampsia in a sample of the subject.

20. The use of any one of claims 1, 2, 14, 15 or 19, wherein the subject does not suffer from pre-eclampsia.